Revacept
Acute Coronary Syndrome
AdvanceCor GmbHPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Acute Coronary Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | BBB |
Lipitor Punjab Institute of Cardology | Phase 4 | BB |
Plavix Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | BB |
Ticagrelor Tianjin Institute of Pharmaceutical Research Co., Ltd | Phase 4 | BB |
Exenatide Saint Luke's Health System | Phase 4 | BB |
View all 34 →
Same molecule, other indications
Revacept is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →